NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

Cipher Pharmaceuticals Inc. (CPH.TO) Stock Analysis

Cipher Pharmaceuticals Inc. (CPH.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

Last Updated: October 21, 2026

CPH.TO

CA$13.31

+CA$0.06 (+0.45%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CPH.TO with… →

CPH.TO Key Statistics

As of Oct 21, 2026
Trading
Open
CA$13.25
Previous Close
CA$13.25
Day's Range
13.25–13.70
52-Week Range
12.48–20.56
Volume
2.99K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.41
Valuation
Market Cap
CA$338.27M
P/E Ratio
8.70
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.82
EPS (ttm)Profit attributable to each share over the last twelve months.
1.53
Financials (FY)
Revenue (FY)
CA$50.45M+51.22%
Net Income (FY)
CA$27.33M+136.72%
Profit marginThe share of revenue left as profit after all costs and taxes.
58.42%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
25.42M
1-Year Return
−10.85%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
36.62K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CPH.TO closed at CA$13.31, −10.85% over 1 year.

Cipher Pharmaceuticals Inc. (CPH.TO) has a market capitalization of CA$338.27M.

In fiscal 2025, CPH.TO reported revenue of CA$50.45M.

CPH.TO Stock Return by Calendar Year

Cipher Pharmaceuticals Inc. (CPH.TO) 10-year return: what CA$10,000 became

1 year
CA$10,000 CA$8,915
−10.85%
5 years
CA$10,000 CA$49,664
+396.64%
10 years
CA$10,000 CA$27,729
+177.29%

If you had invested CA$10,000 in Cipher Pharmaceuticals Inc. (CPH.TO) 10 years ago, at the close on October 21, 2016, it would have been worth CA$27,729 at the close on October 21, 2026: +177.29% in total, +10.74% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−11.62%
2025+5.17%
2024+158.48%
2023+44.27%
2022+116.95%
2021+90.32%
2020−38.00%
2019−12.28%
2018−65.10%
2017+0.00%
2016 (partial year)−25.42%

As of October 21, 2026.

CPH.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$50.45MCA$27.33M54.2%
2024CA$33.36MCA$11.55M34.6%
2023CA$21.16MCA$20.38M96.3%
2022CA$20.68MCA$26.64M128.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$50.45MCA$40.42MCA$16.87MCA$27.33M54.2%
2024CA$33.36MCA$24.10MCA$7.85MCA$11.55M34.6%
2023CA$21.16MCA$17.09MCA$10.30MCA$20.38M96.3%
2022CA$20.68MCA$16.68MCA$11.05MCA$26.64M128.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CPH.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricCPH.TODrug Manufacturers - Specialty & Generic medianvs median
P/E8.7020.3157% below
P/S ratio6.822.103.2x the median
Profit margin58.42%−8.14%66.6 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

Cipher Pharmaceuticals Inc. (CPH.TO) is capitalised at CA$338.27M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.

The most recent close on file for CPH.TO is CA$13.31, dated October 21, 2026. That is +CA$0.06 (+0.45%) against the previous close. Over the past 52 weeks the price has ranged from CA$12.48 to CA$20.56. The latest close sits 6.65% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to CA$50.45M. Against the prior fiscal year total of CA$33.36M, that is a change of +51.22%. Net income for the same year was CA$27.33M. That is +136.72% against the prior fiscal year. Profit margin runs at 58.42%. That is 66.6 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to 1.53.

Across the 4 fiscal years on file, revenue moves from CA$20.68M in 2022 to CA$50.45M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

CPH.TO trades at a trailing price-to-earnings ratio of 8.7. That is 57.17% below the Drug Manufacturers - Specialty & Generic median of 20.31. Measured against sales, the shares trade at 6.82 times revenue. On price-to-sales that is 3.2 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at 0.41. Daily returns over the trailing 10 years annualize to a volatility of 60.83%. The trailing one-year total return is −10.85%. Across 10 years the annualized return works out at +10.74%.

Growth & Income

No dividend is on file for CPH.TO.

So far in 2026 the total return is −11.62%. The strongest complete calendar year on file is 2024 at +158.48%; the weakest is 2018 at −65.10%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Cipher Pharmaceuticals Inc. (CPH.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cipher Pharmaceuticals Inc. CPH.TO CA$338.27M 8.7
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

Market caps are shown in each company's own trading currency, without conversion, and the peers are listed in order of these unconverted figures.

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Cipher Pharmaceuticals Inc. trades at a P/E of 8.7.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients. The company's licensed products comprise Absorica, an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Conzip, an opioid agonist for the management of moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, as well as to increase HDL-C. Its pipeline products include piclidenoson CF-101, a novel chemical entity for moderate to severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; and DTR-001, a tattoo removal cream. The company was founded in 2000 and is headquartered in Mississauga, Canada.

Visit website →